The second largest German pharmaceutical manufacturer, Boehringer Ingelheim it has savings in the pipeline that could lead to the cutting of over 1,000 jobs.
18/09/2014 – Drnet
The news comes from the Frankfurter Allgemeine Zeitung, later confirmed by the company spokesman Philipp Baum: ”it could well happen that in the medium term the jobs are affected” by the reorganization plan. "But corporate-related layoffs will be avoided," he added. According to the newspaper, the pharmaceutical giant is planning a reduction of 15% of expenses, canceling among other things 600 positions between now and 2016, and the rest in the following two years. Boehringer Ingelheim employs 47,500 people worldwide, 14,000 in Germany. In the first six months of 2014, turnover fell by 7.9% compared to the previous year to 6.5 billion euros.
Two areas of the company are expressly excluded from staff reductions: the first is the Biberach biopharmaceutical company, which produces drugs for other companies; the second instead relates to Ingelheim's own production, which had aroused the attention of the FDA so much as to send a "Warning Letter", repealed only later. The interest from the FDA has increased the turnover of that area of the company by about 14 billion euros a year.
Source: Frankfurter Allgemeine Zeitung
